ScholarLens Back to search
2014•MD Conference ExpressRequires access

Treatment with Alemtuzumab Leads to Durable Benefits in Patients with Multiple Sclerosis

Maria Vinall, Douglas Lorne Arnold

Open publisher page 0 citations

Abstract

Treatment with alemtuzumab is associated with durable improvements in magnetic resonance imaging (MRI) disease activity in patients with active relapsing-remitting multiple sclerosis. This article presents the 3-year results from An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (NCT00930553), an ongoing extension study of the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) series of studies.

About this research paper

What this paper is about

Treatment with alemtuzumab is associated with durable improvements in magnetic resonance imaging (MRI) disease activity in patients with active relapsing-remitting multiple sclerosis. This article presents the 3-year results from An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (NCT00930553), an ongoing extension study of the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) series of studies.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Treatment with alemtuzumab is associated with durable improvements in magnetic resonance imaging (MRI) disease activity in patients with active relapsing-remitting multiple sclerosis. This article presents the 3-year results from An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (NCT00930553), an ongoing extension study of the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) series of studies.

Key concepts: Alemtuzumab, Multiple sclerosis, Medicine, Magnetic resonance imaging, Relapsing remitting, Internal medicine, Radiology, Psychiatry

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Treatment with Alemtuzumab Leads to Durable Benefits in Patients with Multiple Sclerosis — Research Paper | ScholarLens